Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CD22 | P20273 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974776 | 0.90 | PKM (0.49) | PKMOPRM1CD22GBA1SENP1 | |
| SCHEMBL24974633 | 0.90 | PKM (0.47) | PKMOPRM1CD22GBA1SENP1 | |
| SCHEMBL24974600 | 0.89 | GBA1 (0.50) | PKMOPRM1SLC6A3CD22GBA1 | |
| SCHEMBL24974781 | 0.88 | SIRT2 (0.48) | PKMOPRM1CD22GBA1SENP1 | |
| SCHEMBL24974743 | 0.88 | OPRM1 (0.48) | PKMOPRM1CD22GBA1SENP1 | |
| SCHEMBL24974540 | 0.84 | PKM (0.47) | PKMOPRM1CD22SENP1SIRT2 | |
| SCHEMBL19006139 | 0.81 | OPRM1 (0.57) | PKMOPRM1CD22GBA1SENP1 | |
| SCHEMBL24974637 | 0.77 | KMT2A (0.48) | KDR | |
| SCHEMBL20090400 | 0.74 | OPRM1 (0.61) | PKMOPRM1SENP1SIRT2F2 | |
| SCHEMBL24974801 | 0.74 | LYPLA2 (0.47) | PKMOPRM1SLC6A3CD22GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | PKM 3656/4885OPRM1 614/4885SLC6A3 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.